Gervasoni J E, Taub R N, Rosado M, Krishna S, Stewart V J, Knowles D M, Bhalla K, Ross D D, Baker M A, Lutzky J
Department of Medicine, Columbia University, New York, NY 10032.
Cancer Chemother Pharmacol. 1991;28(2):93-101. doi: 10.1007/BF00689695.
The glycoproteins on the surface of HL-60/S wild-type, drug-sensitive human leukemia cells and HL-60/AR anthracycline-resistant cells which do not overexpress the P-glycoprotein, were characterized by labeling with [35S]-methionine, NaB[3H4], phosphorus 32, or sodium iodide I 125. HL-60/S and HL-60/AR cell lysates and membrane fractions tagged with [35S]-methionine or phosphorus 32 showed no significant differences in their protein patterns as analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and by autoradiography. HL-60/S cells labeled with NaB[3H4] yielded glycoproteins that were smeared predominantly in the molecular-weight range of 210,000 and 160,000 Da, with pI values ranging between pH 4 and pH 4.4. In contrast, NaB[3H4]-labeled HL-60/AR cells showed 7-8 discrete glycoproteins within a molecular-weight range of 170,000 and 140,000 Da, with pI values also ranging between pH 4 and pH 4.4. In addition, [3H]-glucosamine incorporation into HL-60/S and HL-60/AR cells revealed that the latter showed lower uptake of [3H]-glucosamine than did the former. Following treatment with tunicamycin, [3H]-glucosamine uptake in HL-60/S cells decreased, whereas that in HL-60/AR cells remained unchanged. Surface-membrane radioiodination of HL-60/S and HL-60/AR cells showed two distinct protein electrophoretic patterns, with differences being observed in both the high-(220-95 kDa) and low-molecular-weight ranges (21 kDa). Flow cytometric analysis of HL-60/S and HL-60/AR cells using myeloid and lymphoid antigen-specific antibodies demonstrated no antigenic differences between HL-60/S and HL-60/AR cells. HL-60/S cells incubated in the presence of tunicamycin, an inhibitor of N-linked glycosylation, or the protein kinase C agonist phorbol 12-myristate 13-acetate (PMA) developed a glycoprotein pattern similar to that observed in HL-60/AR cells. In addition, tunicamycin treatment of HL-60/S cells decreased daunorubicin (DNR) retention and altered its intracellular distribution as compared with that in HL-60/AR cells. These data indicate that HL-60/AR cells do not possess either de novo or amplified high-molecular-weight surface-membrane proteins; instead, existing proteins are hypoglycosylated. These results also show that HL-60/AR cells exhibit the multidrug-resistant phenotype in association with altered membrane glycoproteins of both high (220-95 kDa) and low molecular weight (21 kDa), but without overexpression of the P-glycoprotein. Furthermore, in HL-60/S cells, the multidrug-resistant phenotype is partially inducible by inhibition of N-linked glycosylation of cell-surface proteins.
用[35S]-甲硫氨酸、NaB[3H4]、磷32或碘化钠I 125对HL-60/S野生型、药物敏感的人白血病细胞以及不高表达P-糖蛋白的HL-60/AR蒽环类耐药细胞表面的糖蛋白进行了表征。用[35S]-甲硫氨酸或磷32标记的HL-60/S和HL-60/AR细胞裂解物及膜组分,经十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)和放射自显影分析,其蛋白质图谱无显著差异。用NaB[3H4]标记的HL-60/S细胞产生的糖蛋白主要分布在分子量为210,000和160,000 Da的范围内,pI值在pH 4至pH 4.4之间。相比之下,用NaB[3H4]标记的HL-60/AR细胞在分子量为170,000和140,000 Da的范围内显示出7 - 8种离散的糖蛋白,pI值也在pH 4至pH 4.4之间。此外,[3H]-葡萄糖胺掺入HL-60/S和HL-60/AR细胞的实验表明,后者对[3H]-葡萄糖胺的摄取低于前者。用衣霉素处理后,HL-60/S细胞中[3H]-葡萄糖胺的摄取减少,而HL-60/AR细胞中的摄取保持不变。HL-60/S和HL-60/AR细胞的表面膜放射性碘化显示出两种不同的蛋白质电泳图谱,在高分子量范围(220 - 95 kDa)和低分子量范围(21 kDa)均观察到差异。使用髓系和淋巴系抗原特异性抗体对HL-60/S和HL-60/AR细胞进行流式细胞术分析表明,HL-60/S和HL-60/AR细胞之间无抗原性差异。在N-连接糖基化抑制剂衣霉素或蛋白激酶C激动剂佛波醇12-肉豆蔻酸酯13-乙酸酯(PMA)存在下孵育的HL-60/S细胞,其糖蛋白图谱与HL-60/AR细胞中观察到的相似。此外,与HL-60/AR细胞相比,衣霉素处理HL-60/S细胞可降低柔红霉素(DNR)的潴留并改变其细胞内分布。这些数据表明,HL-60/AR细胞既不具有从头合成或扩增的高分子量表面膜蛋白;相反,现有蛋白的糖基化程度较低。这些结果还表明,HL-60/AR细胞表现出多药耐药表型,与高分子量(220 - 95 kDa)和低分子量(21 kDa)的膜糖蛋白改变有关,但P-糖蛋白未过表达。此外,在HL-60/S细胞中,细胞表面蛋白N-连接糖基化的抑制可部分诱导多药耐药表型。